Pharmacy Times
NOVEMBER 8, 2023
Atta Chowdhry, RPh, and Robert Sidonio Jr, MD, MSc, discuss the emergence of gene therapy as an exciting option for patients with hemophilia A and highlight benefits, limitations, and ongoing research in the field.
Drug Topics
NOVEMBER 8, 2023
The drug, Zepbound, will be available in the United States by the end of 2023.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
NOVEMBER 8, 2023
Tirzepatide is already approved under the brand name Mounjaro (Lilly) to be used along with diet and exercise to improve blood sugar in adults with type 2 diabetes.
STAT
NOVEMBER 8, 2023
Vaccines work well to prevent cancers caused by the human papillomavirus (HPV). So well, in fact, that it may be time to review HPV screening protocols, according to the somewhat provocative conclusion of a new study examining the occurrence of genital HPV types eight years after immunization, published today in Cell Host & Microbe. The randomized control study included more than 60,000 women from 33 Finnish communities born in 1992, 1993, and 1994.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
NOVEMBER 8, 2023
A study found that a pharmacist-prescribing intervention for high blood pressure could save the health care system $1.137 trillion over a 30-year period.
STAT
NOVEMBER 8, 2023
Eli Lilly’s blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been cleared to treat obesity, making it the second in a highly effective class of weight loss medications to enter the market. The Food and Drug Administration’s long-awaited approval of the drug, which will be marketed under the name Zepbound for obesity, is a major milestone for Lilly.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
NOVEMBER 8, 2023
When Ken Song was getting ready to leave his job as the CEO of a small biotech in 2020, he wasn’t sure what was next. But he knew one thing. “I deliberately said I’m not going to do oncology. Oncology is so crowded. Everybody thinks they have the solution, but the reality is, it’s all noise,” he said. That was until late March 2020, when he received two phone calls from two different investors, both pondering about the same thing: Was it possible to make more e
Fierce Healthcare
NOVEMBER 8, 2023
Legislative spotlight was put back on pharmacy benefit manager reform and mental health in a comprehensive draft packaged presented by the Senate Finance Committee, which was passed Wednesday 26-0. | A comprehensive healthcare package garnered near unanimous approval on Wednesday, which could lead to big changes for PBMs down the road.
STAT
NOVEMBER 8, 2023
The opioid crisis rocked America, bringing addiction and overdose into the spotlight. But it also highlighted the overtreatment of pain: Medical and dental providers alike overprescribed opioids after procedures and for chronic conditions. Out of that overtreatment came an epidemic. In American health care, overtreatment is common. Recently though, there has been a subtle shift in the opposite direction.
Fierce Pharma
NOVEMBER 8, 2023
In the Big Pharma battle to treat obesity, Novo Nordisk sprinted to an early lead, but Eli Lilly is catching up quickly. | In the Big Pharma battle to treat obesity, Novo Nordisk sprinted to an early lead, but Eli Lilly is catching up quickly. Wednesday's FDA approval of Lilly's Zepbound to treat obesity closes the gap further. In addition, Lilly said it will charge 20% less than Novo for its obesity med in an attempt to provide increased access.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
NOVEMBER 8, 2023
WASHINGTON — With the prevalence of some chronic diseases trending up, the U.S. needs to revamp its approaches to preventative care and disease management, experts said at the Milken Future of Health Summit on Tuesday. Already, 6 in 10 Americans live with a chronic condition , and 4 in 10 live with at least two. Factors such as the U.S.’s aging population, delayed care during Covid-19, and the rising prevalence of obesity are only exacerbating the problem, said Karen Hacker, the Ce
Pharmacy Times
NOVEMBER 8, 2023
CD4+ tissue-resident memory T cells may trigger severe, and potentially fatal, asthma attacks in men aged 40 years and older.
STAT
NOVEMBER 8, 2023
LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan. “Would I have liked the stock market reaction to be more generous?
Fierce Healthcare
NOVEMBER 8, 2023
Mass General Brigham tapped retailer Best Buy Health to scale up its Healthcare at Home services to meet growing demand for home-based care and address workforce shortages. | Mass General Brigham tapped retailer Best Buy Health to scale up its Healthcare at Home services to transition more medical care to patients' homes while also addressing workforce shortages.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
NOVEMBER 8, 2023
The therapy, an infusion of CAR-T cells designed to kill the lymphoma, was going well. Nearly a month after the treatment, the engineered cells had crushed the cancer, and the patient, a 49-year-old woman in the Netherlands, appeared to be cancer-free. But two weeks later, something was wrong. The patient couldn’t remember having been in the hospital or, indeed, ever being treated for lymphoma.
Fierce Pharma
NOVEMBER 8, 2023
In three years as the pharma chief at Roche, Bill Anderson executed a massive overhaul of the division, lopping off layers of management and recharting its course. | In three years as the pharma chief at Roche, Bill Anderson executed a massive overhaul of the division, lopping off layers of management and recharting its course. Now in his fifth month as CEO at struggling conglomerate Bayer, Anderson is focused on an even larger renovation, saying the company is on its way to a “radical realignme
STAT
NOVEMBER 8, 2023
Curie.Bio, the new biotech investment firm and incubator launched earlier this year by a group of industry veterans including Alexis Borisy and Zach Weinberg, has graduated its first startup. The startup, Forward Therapeutics, is coming out of the incubator with three drug candidates for chronic inflammatory disorders. It also just closed its first major financing round: a $50 million Series A round led by BVF Partners, with participation from RA Capital Management and OrbiMed.
Drug Topics
NOVEMBER 8, 2023
In a recent Morbidity and Mortality Weekly Report (MMWR), the results of a study showed 63% of those who died from HAV had at least 1 documented preexisting indication for vaccination.
STAT
NOVEMBER 8, 2023
WASHINGTON — A prominent Senate panel on Wednesday passed a new package of health policy reforms that would rein in certain pharmacy middlemen practices and ensure Medicare patients aren’t paying more than insurers do for medications. The package passed the committee 26-0 with no amendments added. Sen. Ron Johnson (R-Wis.) didn’t vote.
Pharmacy Times
NOVEMBER 8, 2023
Regular usage of cannabis may increase the risk of heart failure, stroke, or heart attack, even after adjusting for other cardiovascular disease risk factors.
STAT
NOVEMBER 8, 2023
WASHINGTON — It’s easy to get people worked up about cures, but they don’t seem to be bothered by falling life expectancy, and Food and Drug Administration Commissioner Robert Califf would like to figure out how to connect the two. The United States has one of the lowest life expectancy rates among wealthy nations. Post-pandemic, the average American life span is down to 76.4 years.
Fierce Pharma
NOVEMBER 8, 2023
While Biogen CEO Chris Viehbacher seems satisfied with the company's third-quarter financial metrics, the main question at the drugmaker isn’t so much how the company’s doing now, but what its plan | While Biogen CEO Chris Viehbacher seems satisfied with the company's third-quarter financial metrics, the main question at the drugmaker isn’t so much how the company’s doing now, but what its plans are for future growth, he said on a call with investors.
STAT
NOVEMBER 8, 2023
The term “excited delirium” has been used for years by law enforcement and other first responders, including health care workers, to describe people who exhibit behavior that is considered “out of control.” This diagnosis has been applied again and again, even posthumously, as a justification for extreme, and sometimes deadly, interventions by law enforcement.
Drug Store News
NOVEMBER 8, 2023
Patrick Morrow, founder of Tini Naturals, has a goal to prevent no less than 100 tons of plastic from negatively impacting the environment in their first year of production alone.
STAT
NOVEMBER 8, 2023
The Food and Drug Administration approved a surgical system used to reduce blood pressure from Recor Medical, the company announced Wednesday. The treatment, called renal denervation, is controversial in the cardiology community due to its unclear efficacy. Renal denervation is a treatment for patients who cannot manage standard doses of blood pressure medication — whether because the drugs aren’t effective enough for them, create overwhelming side effects, or become too cumbersome
Drug Store News
NOVEMBER 8, 2023
The new benefit includes care from One Medical, including 24/7 on-demand virtual care nationwide and easy to schedule office visits at any of One Medical’s hundreds of locations across the United States.
Fierce Healthcare
NOVEMBER 8, 2023
Moody’s Investor Services is forecasting stronger financials across the nonprofit hospital sector in 2024 thanks to upticks in reimbursement rates and volumes that will outpace continued labor expe | The ratings agency said it anticipates a 10% to 20% increase in nonprofit providers' median operating cash flow during the coming year. Median operating revenue is projected to grow between 4% and 6% while median operating costs are forecasted between 3% to 5%.
Pharmacy Times
NOVEMBER 8, 2023
More individuals who used e-cigarettes have reported pulmonary diseases compared with those who never smoked, including asthma.
Drug Store News
NOVEMBER 8, 2023
Clinical studies from the Integrative Dermatology Symposium showcase how ingredients from nature support the lip and skin microbiome, in addition to improving the appearance of age spots and hyperpigmentation.
STAT
NOVEMBER 8, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a close look at an en-vogue idea in oncology, an awkward welcome for a new CEO, and a twist on the classic drug pricing backlash.
PharmExec
NOVEMBER 8, 2023
Tirzepatide (Zepbound; Eli Lilly and Company) is expected to be available in the United States by the end of 2023 with a list price of $1,059.87.
Drug Store News
NOVEMBER 8, 2023
The retail giant said it is enacting sensory-friendly hours at all of its locations after a successful test program during the recent back-to-school shopping season.
Fierce Healthcare
NOVEMBER 8, 2023
Amazon's push into healthcare has focused on making medical services more affordable and convenient. | Building on its One Medical deal, Amazon is now offering a One Medical for Prime membership, including 24/7 virtual care, for $9 per month, or $99 a year.
Pharmacy Times
NOVEMBER 8, 2023
Changes in gene expression could ultimately boost the production of inflammatory cytokines.
Expert insights. Personalized for you.
158 
Let's personalize your content